Log in
OTCMKTS:ZYXI

Zynex Stock Forecast, Price & News

$13.87
+0.45 (+3.35 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.43
Now: $13.87
$13.96
50-Day Range
$12.81
MA: $14.23
$19.73
52-Week Range
$7.51
Now: $13.87
$29.73
Volume234,192 shs
Average Volume784,177 shs
Market Capitalization$481.86 million
P/E Ratio63.05
Dividend YieldN/A
Beta1.05
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Read More
Zynex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZYXI
CUSIPN/A
Phone303-703-4906
Employees283

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.43 million
Cash Flow$0.77 per share
Book Value$0.15 per share

Profitability

Net Income$7.36 million

Miscellaneous

Market Cap$481.86 million
Next Earnings DateN/A
OptionableNot Optionable
$13.87
+0.45 (+3.35 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zynex (OTCMKTS:ZYXI) Frequently Asked Questions

How has Zynex's stock been impacted by COVID-19 (Coronavirus)?

Zynex's stock was trading at $11.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZYXI shares have increased by 25.1% and is now trading at $13.87.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zynex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zynex
.

What stocks does MarketBeat like better than Zynex?

Wall Street analysts have given Zynex a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zynex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Zynex's earnings last quarter?

Zynex, Inc. (OTCMKTS:ZYXI) released its quarterly earnings data on Tuesday, October, 27th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by $0.01. Zynex had a return on equity of 152.81% and a net margin of 33.33%.
View Zynex's earnings history
.

What guidance has Zynex issued on next quarter's earnings?

Zynex updated its fourth quarter 2020 After-Hours earnings guidance on Tuesday, October, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.5-26.5 million, compared to the consensus revenue estimate of $25.85 million.

What price target have analysts set for ZYXI?

4 analysts have issued 12-month price objectives for Zynex's stock. Their forecasts range from $22.50 to $30.00. On average, they expect Zynex's share price to reach $26.38 in the next twelve months. This suggests a possible upside of 90.2% from the stock's current price.
View analysts' price targets for Zynex
.

Who are some of Zynex's key competitors?

What other stocks do shareholders of Zynex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include Advanced Micro Devices (AMD), Pfizer (PFE), Farfetch (FTCH), K12 (LRN), AbbVie (ABBV), Activision Blizzard (ATVI), Big Lots (BIG), ChromaDex (CDXC), Chegg (CHGG) and Dell Technologies (DELL).

Who are Zynex's key executives?

Zynex's management team includes the following people:
  • Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 61, Pay $523.04k)
  • Mr. Daniel J. Moorhead, Chief Financial Officer (Age 48, Pay $352.86k)
  • Mr. Joseph Papandrea, Chief Operating Officer (Age 47, Pay $272.31k)
  • Ms. Chelle Van Burkleo, VP of Sales
  • Mr. Neil Friery, Pres & COO of Zynex Monitoring Solutions, Inc.
  • Mr. Joachim Sandgaard, Information Systems Mang.

What is Zynex's stock symbol?

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

Who are Zynex's major shareholders?

Zynex's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.92%), State Street Corp (1.46%), Punch & Associates Investment Management Inc. (1.18%), Wells Fargo & Company MN (0.99%), Oak Ridge Investments LLC (0.77%) and Charles Schwab Investment Management Inc. (0.46%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard.
View institutional ownership trends for Zynex
.

Which institutional investors are selling Zynex stock?

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Cadence Capital Management LLC, Mackay Shields LLC, AQR Capital Management LLC, State of Tennessee Treasury Department, and Trexquant Investment LP.
View insider buying and selling activity for Zynex
.

Which institutional investors are buying Zynex stock?

ZYXI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Oak Ridge Investments LLC, Wells Fargo & Company MN, SG Americas Securities LLC, Charles Schwab Investment Management Inc., Royce & Associates LP, Squarepoint Ops LLC, and Massachusetts Financial Services Co. MA.
View insider buying and selling activity for Zynex
.

How do I buy shares of Zynex?

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zynex's stock price today?

One share of ZYXI stock can currently be purchased for approximately $13.87.

How big of a company is Zynex?

Zynex has a market capitalization of $481.86 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. Zynex employs 283 workers across the globe.

What is Zynex's official website?

The official website for Zynex is www.zynexmed.com.

How can I contact Zynex?

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.